Watch UNCY. Know when insiders buy.
One email the day a filing lands. Free.
UNCY
Unicycive Therapeutics, Inc.
4.55
−0.14 −3.09%
USD · close Oct 1
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
65
PASS · shorts 65
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $126.7MP/E —DIV YIELD —FCF YIELD -21.97%REV TTM —NET INCOME −$35.2MNET CASH —52W 4.44 – 8.56SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$10.1M | −$1.7M | — | -0.06 | −$7.6M | −$1K | −$7.6M | Aug 12 |
| Q1 2026 · Mar 31 | — | — | — | −$8.4M | −$12.8M | −2349.6% | -0.54 | −$6.2M | $8K | −$6.2M | Aug 12 |
| Q4 2025 · Dec 31derived | — | — | — | −$7.2M | −$14.7M | — | -0.82 | −$8M | $0 | −$8M | Mar 30 |
| Q3 2025 · Sep 30 | — | — | — | −$7.3M | −$6M | — | -0.33 | −$6M | $2K | −$6M | Nov 12 |
| Q2 2025 · Jun 30 | — | — | — | −$7M | −$6.4M | −165.4% | -0.52 | −$8.4M | $6K | −$8.4M | Aug 12 |
| Q1 2025 · Mar 31 | — | — | — | −$8M | $570K | — | -0.50 | −$8.9M | $16K | −$8.9M | Aug 12 |
| Q4 2024 · Dec 31derived | — | — | — | −$9.3M | −$21.5M | — | -2.64 | −$6.5M | $22K | −$6.6M | Mar 30 |
| Q3 2024 · Sep 30 | — | — | — | −$6.3M | −$4.1M | — | -0.46 | −$9.3M | $24K | −$9.3M | Nov 12 |
| Q2 2024 · Jun 30 | — | — | — | −$7.4M | $9.9M | — | -1.50 | −$6.3M | $20K | −$6.3M | Nov 12 |
| Q1 2024 · Mar 31 | — | — | — | −$9.2M | −$21M | — | -0.61 | −$6.5M | $6K | −$6.5M | Nov 12 |
| Q4 2023 · Dec 31derived | $0 | — | — | −$6.3M | −$7.8M | — | -0.16 | −$4.4M | $0 | −$4.4M | Mar 31 |
| Q3 2023 · Sep 30 | $0 | — | — | −$5.9M | −$4.3M | — | -0.13 | −$4.4M | $0 | −$4.4M | Nov 13 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$29.5M | −$26.6M | — | -1.67 | −$31.3M | $24K | −$31.3M | — | — |
| FY2024 · to Dec 31 | — | — | −$32.1M | −$36.7M | — | -5.65 | −$28.6M | $72K | −$28.6M | — | $1.1M |
| FY2023 · to Dec 31 | $675K | — | −$20.8M | −$30.5M | -4525.0% | -1.28 | −$18.3M | $12K | −$18.3M | — | $900K |
| FY2022 · to Dec 31 | $951K | — | −$18.1M | −$18.1M | -1898.8% | -1.20 | −$15.7M | $2K | −$15.7M | — | — |
| FY2021 · to Dec 31 | — | — | −$9M | −$10M | — | -0.86 | −$5.8M | $29K | −$5.8M | — | — |
| FY2020 · to Dec 31 | — | — | −$2M | −$2.3M | — | -0.27 | −$1.5M | — | — | — | — |
Every number comes from Unicycive Therapeutics, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.